Chowist Web Search

Search results

1. Results From The WOW.Com Content Network

2. Apixaban - Wikipedia

   en.wikipedia.org/wiki/Apixaban

   Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. [6] [7] [8] Specifically, it is used to prevent blood clots following hip or knee replacement and in those with a history of ...

3. U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the ... - AOL

   www.aol.com/news/2013-01-02-us-fda-approves...

   In patients with any two of the following characteristics (age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5mg/dL), the recommended dose of ELIQUIS is 2.5 mg twice daily. The dose ...

4. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   Medical use. Direct factor Xa inhibitors include rivaroxaban, apixaban and edoxaban, and are types of direct oral anticoagulant (DOAC), which are blood thinning drugs, one of the classes of antithrombotic drugs. [4] [5] [6] They are commonly prescribed to treat and prevent blood clots in veins, prevent stroke and embolism in people with non ...

5. Lorazepam - Wikipedia

   en.wikipedia.org/wiki/Lorazepam

   0.5 mg tablets of the Ativan brand of lorazepam. Pure lorazepam is an almost white powder that is nearly insoluble in water and oil. In medicinal form, it is mainly available as tablets and a solution for injection, but, in some locations, it is also available as a skin patch, an oral solution, and a sublingual tablet.

6. ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A ...

   www.aol.com/news/2012-12-08-eliquis-apixaban...

   For the primary efficacy outcome, ELIQUIS demonstrated superiority versus placebo (11.6% in the placebo group, compared with 3.8% and 4.2% in the ELIQUIS 2.5 mg and 5 mg groups, respectively, P<0. ...

7. ELIQUIS® (apixaban) Demonstrates Consistent Reductions in ...

   www.aol.com/2012/10/01/eliquis-apixaban...

   Patients were randomized to treatment with ELIQUIS 5 mg orally twice daily (or 2.5 mg twice daily in selected patients, representing 4.7 percent of all patients) or warfarin (target INR range 2.0 ...

8. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Discovery and development of direct Xa inhibitors. Four drugs from the class of direct Xa inhibitors are marketed worldwide. Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States ...

9. Bristol-Myers Squibb and Pfizer Announce Publication of ...

   www.aol.com/news/2013-05-06-bristol-myers-squibb...

   Patients were randomized to treatment with Eliquis 5 mg orally twice daily (or 2.5 mg twice daily in selected patients, representing 4.7 percent of all patients) or warfarin (target INR range 2.0 ...